The BCR/ABL oncogenic tyrosine kinase is responsible for initiating and maintaining the leukemic phenotype of Philadelphia chromosome (Ph')-positive cells. Phosphatidylinositol-3 (PI-3) kinase is known to interact with and be activated by receptor and nonreceptor tyrosine kinases. We investigated whether PI-3 kinase associates with and/or is regulated by BCR/ABL, whether this interaction is functionally significant for Ph' cell proliferation, and, if so, whether inhibition of PI-3 kinase activity can be exploited to eliminate Ph'-positive cells from bone marrow. We show that the p85a subunit of PI-3 kinase associates with BCR/ABL and that transient expression of BCR/ABL in fibroblasts and downregulation of BCRlABL expression using antisense oligodeoxynucleotides (ODNs) in Ph' cells activates and inhibits, respectively, PI-3 kinase enzymatic activity. The use of specific ODNs or antisense constructs to downregulate p85a expression showed a requirement for p85a subunit in the proliferation of BCR/ABL-dependent cell lines and chronic HE BCWABL HYBRID GENES generate fusion proteins in which the NH2-terminal region of c-abl is replaced by a bcr fragment truncated at exon 3, exon 2 (p210bcr'ab'), or exon 1 (p185bcr'0b').1-3 These fusion proteins can transform immature hematopoietic cells," cause chronic myelogenous leukemia (CML) or acute leukemia syndromes in m i~e j .~ and are necessary for the growth of human CML cells in vitro and in V~V O .~,~ The transforming ability of BCW ABL proteins, localized mainly in the cytoplasm: depends on their tyrosine kinase activity." The identification of the substrates involved in transducing the oncogenic signals initiated by the BCWABL tyrosine kinase is likely to shed light on the mechanisms of leukemogenesis and may reveal new targets for antileukemia therapy.
Several potential BCWABL targets, such as GRB-2," Shc," P~~R A S , '~. '~ p120GAP,"." p160BCR,"j CRKL,I7 c-M~C , " . '~ and c-Myb2' have already been identified. In this report, we analyze the role of phosphatidylinositol-3 (PI-3) kinase in BCWABL-mediated leukemogenesis and normal myelogenous leukemia (CML) primary cells. Similarly, wortmannin, a specific inhibitor of the enzymatic activity of the p110 subunit of PI-3 kinase, inhibited growth of these cells. The growth of normal bone marrow and erythromyeloid, but not megakaryocyte, progenitors was inhibited by p85a
antisense ISlODNs, but wottmannin, at the concentrations tested, did not affect normal hematopoiesis. The proliieration of two BCR/ABL-and growth factor-independent cell lines was not affected by downregulation of the expression of the p85a subunit or inhibition of p110 enzymatic activity, confirming the specificity of the observed effects on Ph' cells. Thus, PI-3 kinase is one of the downstream effectors of BCR/ABL tyrosine kinase in CML cells. Moreover, reverse transcriptase-polymerase chain reaction performed on single colonies to detect BCR-ABL transcripts showed that wortmannin was able to eliminate selectively CML-blast crisis cells from a mixture of normal bone marrow and Ph' cells. 0 1995 by The American Society of Hematology.
hematopoiesis. PI-3 kinase phosphorylates the D-3 position of the inositol ring of phosphoinositols and produces novel D-3 phosphoinositides (PI-3P, PI-3P2, and PI-3,4P3).2' It has been proposed that 3'-phosphorylated inositides represent a class of second messenger molecules whose function and interaction with other proteins remain to be elucidated. PI-3 kinase, found in cellular complexes with ligand-activated growth factor receptors and oncogene protein tyrosine kinases (PTKs),~~ is a heterodimer composed of a p85 (regulatory) and a p110 (catalytic) subunit.23 The former, which contains SH2 and SH3 domains, acts as an adaptor protein allowing the p1 10 catalytic subunit to interact with receptor and nonreceptor PTKs and tyrosine-phosphorylated proteins, resulting in the activation of PI-3 kinase enzymatic a~tivity.'~ p85 may function also as an adaptor for other proteins involved in signal transduction." A role for PI-3 kinase in mitogenesis, cell transformation, and other cellular events involving PTKs has been proposed, based on the observation that normal and oncogenic PTKs that retain the enzymatic activity but do not associate with or activate PI-3 kinase are neither mitogenically activated by the respective ligands nor do they mediate tran~formation.~~*~' However, not all ligandstimulated receptors need PI-3 kinase for the proliferative response. 28 The observation that the p85a subunit coimmunoprecipitates with BCWABL in a CML cell line33 and that PI-3 kinase activity increased in fibroblasts transfected with ABL oncogenic variants34 suggests involvement of PI-3 kinase in BCWABL-mediated leukemogenesis. Ligand stimulation of c-kit, erythropoietin (Epo), interleukin-3/granulocyte-macrophage colony-stimulating factor (IL-3/GM-CSF), or macrophage-CSF (M-CSF) receptors causes association of the receptor and activation of PI-3 k i n a~e ,~~.~' suggesting that the kinase may also play a role for the proliferatioddifferentiation of normal hematopoietic cells. However, the possible role of PI-3 kinase in normal and Philadelphia chromosome
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In this article, we report direct evidence that PI-3 kinase activity is not only regulated by BCWABL in CML cells, but also plays a major role in the BCWABL-dependent proliferation of these cells.
MATERIALS AND METHODS
Primary cells. Bone marrow cells were obtained by aspiration from the iliac crest of healthy volunteers and from patients with CML-blast crisis (CML-BC), CML-accelerated phase (CML-AP), and CML-chronic phase (CML-CP) after informed consent. Mononuclear cells (MNCs) were separated on Histopaque-1077 (Sigma Chemical CO, St Louis, MO) density gradient and were enriched for hematopoietic progenitors after removing the majority of adherent cells and T lymphocytes (A-T-MNC) as de~cribed.~' CD34+ cells were isolated using AIS MicroCELLector T-25 cell culture flasks (Applied Immune Sciences, Inc, Menlo Park, CA) according to the manufacturer's protocol. The yield of CD34' cells from CML cells and nonadherent T-lymphocyte-depleted bone marrow cells (A-T-BMC) ranged between 5% to 45% and 0.3% to 3% of the starting MNC populations, respectively.
Cell lines. The BV173 and K562 cells with t(9;22) chromosomal translocation, established from patients with CML-BC, the NB4 promyelocytic leukemia with t( 15;17) chromosomal translocation, and the HL-60 promyelocytic leukemia cells, were maintained in RPMI Plasmids. The full length (7.0-kb) bcr exon 3/abl exon 2 cDNA was cloned into the pSV plasmid (pSV-bcrfabl) under the control of the SV40 early promoter. The 373-bp fragment of p85a cDNA (nucleotides 35-408) was cloned into the pcDNA3 plasmid in the sense or antisense orientation (pcDNA3-p85a S and pcDNA3-p85a AS, respectively).
[SIODNs and wortmnnin (W) treatment of the cells. 10' CML cells or A-T-BMC was seeded into 24-well culture plates (Costar Corp, Cambridge, MA) in 0.4 mL Iscove's modified Dulbecco's medium supplemented with 2% heat-inactivated human AB serum (GIBCO, BRL, Grand Island, NY), and HEPES buffer. Sense or antisense p85a [SIODNs were added at a concentration of 80 pg/ mL at the beginning of culture, and at 40 p g / d 24 and 48 h later. The PI-3 kinase inhibitor WT (Sigma) was dissolved in dimethyl sulfoxide (DMSO) and added to the cultures at the concentration of 0.25 p m o K each day, because of its in~tability,~' for 4 consecutive days. At this concentration, WT inhibited PI-3 kinase enzymatic activity by more than W%, as assessed in kinase assays on anti-p85 immunoprecipitates from CML cells and A-T-MNC (not shown). Control cells were incubated with the same concentrations of DMSO. Recombinant human IL-3 (generous gift of Genetics Institute, cambridge, MA) was added (50 U/mL) to primary CML cell cuhres, when indicated, together with the third dose of [SlODNs, or at the beginning of the culture with WT. The indicated recombinant human growth factors: IL-3 (50 U/mL), GM-CSF (12.5 ng/mL; Genetics Institute), L-5 (1 : 1 , OOO conditioned medium from a Chinese hamster ovary cell line constitutively expressing a human IL-5 cDNA; Genetics Institute), M-CSF (50 U/mL; Genetics Institute), G-CSF (1: 10,OOO conditioned medium from a Chinese hamster ovary cell line constitutively expressing a human G-CSF cDNA; Genetics Institute), stem cell factor SCF 1 0 0 ng/mL; Immunex Corp, Seattle, WA), IL-6 (125 U/mL; Genetics Institute), Epo (2 U/mL, Amgen, Inc, Thousand Oaks, CA), were added similarly to the A-T-MNC cultures. Cells were incubated for 24 hours after the last dose of [SIODNs or WT and then plated in semisolid methylcellulose medium HCC 4230 (Terry Fox Labs, Vancouver, Canada) in duplicate 35-mm Petri dishes, without washing. All colonies were scored on days 9 to 12 except those growing with Epo (erythroid colonyforming units), which were counted on days 7 to 9, as previously described." Cells of established lines (triplicates 10?100 pL) were incubated in 96-well microtiter plates in the presence of p85a [ S ] -ODNs, WT, or DMSO or were left untreated. The number of viable cells was evaluated microscopically using trypan blue exclusion vital dye.
Transfections. Exponentially growing cells were transfected by electroporation with sense or antisense pcDNA3-p85a plasmids and maintained in medium for 48 hours. After 7-day selection with medium containing 0.8 mg/mL (3418, cells were cultured in a RPMI 1640 supplemented with 10% FBS or in semisolid medium (HCC 4230). both with 1.6 mg/mL (3418. The number of viable cells and colonies were counted, respectively, at the indicated times. Tk-tsl3 cells were transfected with pSV-bcr/abl or pSV plasmid using the calcium-phosphate precipitation method as described previously."
Immunoprecipitation and Western blotting. Cells (2 X lo6) were solubilized in lysis buffer (10 mmoK HEPES, pH 7.5; 0.15 m o m NaC1; 1% NP-40; 10% glycerol; 10 pg/mL each leupeptin and aprotinin [Sigma]; 1 mmol/L phenylmethylsulfonyl fluoride; 1 mmoY L NaVO,; and 5 mmom EDTA). When indicated, lysates were immunoprecipitated with rabbit anti-p85 polyclonal antibody (UBI, Lake Placid, NY), as previously de~cribed.'~ Postnuclear lysates or immunoprecipitates were separated on 7.5% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose (MCI, Westboro, MA). Filters were saturated with 0.5% nonfat dry milk in Tris-buffered saline (TBS) and incubated plyclonal antibody (Cappel, Organon Technica Corp. West Chester, PA), respectively. After precipitation, the beads were washed twice in lysis buffer, twice in buffer containing 0.5 mol/L LiCl and 0.2% NP-40, and, finally, in 10 mmol/L HEPES and 0.15 mol/L NaCI. Then, 30 pL of 10 mmol/L phenyl phosphate were added, and the eluate was used for PI-3 kinase assay. After a 15-minute incubation at room temperature in the presence of 0.2 mglmL phosphatidylinositol, 40 pmol/L adenosine triphosphate, 30 mmol/L MgCl?, and 10 pCi of [y-"Pladenosine triphosphate, the reaction was stopped by adding 1 0 0 pL 1 N HCI, and lipids were extracted with 200 pL chloroform/methanol ( 1 : I vollvol). After 1 wash with methanolll N HCI (1: 1, vollvol), the lipids in the organic phase were separated by thin layer chromatography using silica gel G60 (J.T. Baker Inc. Phillipsburg, NJ). The thin layer chromatography was developed in chlorophorm/methanol/H~O/NH,OH (43:38:7:5 vlv). Radioactive PI-phosphate (PIP) products were visualized by autoradiography and quantitated using an UltroScan XL apparatus.
Single-colony reverse transcriptase-polymerase chain reaction (RT-PCR) ana/ysis. CML-BC1 cells were mixed I:] with A-T-MNC, treated with WT as described, and plated in the presence of IL-3. Single colonies were picked separately, and the expression of BCWABL and P-actin mRNAs in each colony was examined by RT-PCR followed by Southern blotting of the amplified products as described."
RESULTS

Regulation of PI-3 kinase activiry
by BCWABL. In agreement with a previous report'3 the PI-3 kinase p85 sub-SKORSKI ET AL unit coprecipitated with BCWABL in whole cell lysates from Ph' cell lines (Fig I) . An identical complex was also detected in CML-BC primary cells (Fig l) , raising the possibility that PI-3 kinase is regulated by BCWABL. To test this hypothesis, we analyzed PI-3 kinase activity in the Ph'-positive cell line BV 173 in which BCWABL expression had been downregulated after exposure to bcr/abl-specific antisense [S]-ODNs and in Tk-ts13 cells in which transient expression of BCWABL tyrosine kinase had been induced on transfection of the full-length bcr/abl cDNA driven by the SV40 early promoter. BV 173 and Tk-ts 13 cells were chosen because of their exquisite sensitivity to BCWABL deprivation and their high transfection efficiency, respectively.
In bcr-ab/ antisense [SIODNs-treated BV173 cells, we observed a specific downregulation of BCWABL, but not HSP, protein levels (Fig 2A) ; an 80% to 90% decrease in PI-3 kinase activity was simultaneously detected in the antiphosphotyrosine immunoprecipitates from the same cells, as indicated by the lower amounts of PIP products generated in a kinase reaction (Fig 2A) . Conversely, in cells expressing a functional BCWABL protein with high tyrosine kinase activity (not shown), PI-3 kinase activity in the antiphosphotyrosine immunoprecipitates was significantly increased over that of the parental insertless transfected cells (Fig 2B) .
Effect of inhibition of p85a expression on proliferation of BCWABL-dependent and normal hematopoietic cells. The experiments above, although suggestive, do not prove a direct involvement of PI-3 kinase in BCWABL-dependent effects. To determine whether p85a expression is required for BCWABL-dependent proliferation of hematopoietic cells, we analyzed whether BV173 (Ph', BCWABL-dependent), Al3L-dependent), and HL-60 and NB4 cells (BCWABL-independent) proliferate in conditions in which p85a expression is downregulated, ie, after incubation with p85a antisense [S]-ODNs or transfection with an antisense p85a construct. In BV173 or HL-60 cells incubated with p85a-specific antisense [SIODNs for 72 hours, we detected an -90% reduction of p85a mKNA levels, a . determined by KT-PCK (data not shown), and a 75% to 90% inhibition of p85a protein levels after Western blotting, with no effects on HSP levels (Fig 3A) . This was accompanied by -75% inhibition of PI-3 kina.e activity (Fig 3C) . Compared with controls, proliferation of BV173, DAGMBCWABL, and BaMBCWARL cells wa. completely inhibited, whereas that of HL-60 and NB4 cells was unchanged (Fig 4A) BV173 and HL-60 cells were transfected with pcDNA3 plasmids containing a 373-bp fragment of p85a cDNA in the sense or antisense orientation and the neomycin-resistance gene driven by the cytomegalovirus (CMV) promoter. Expression of the p85a sense and antisense transcripts was confirmed by RT-PCR in cells rescued after 7-day selection in 800 pg/mL G418 (not shown). p85a levels were significantly lower in cells transfected with the p85a-antisense than in those transfected with the p85a-sense construct (Western blotting, Fig 3B) , whereas HSP levels detected on the same filter were essentially identical in both transfectants. Proliferation and colony formation in semisolid medium of BV 173, but not HL-60, cells transfected with the p85a-antisense construct was inhibited compared with that of cells bearing the p85a-sense construct (Fig 4B) .
Growth of primary CML cells used in these studies depends on BCWABL expression, as shown by inhibition of colony formation in semisolid culture in the presence of bcrab1 junction-specific antisense [SIODNs, conditions in which 729 downregulation of bcrhhl mRNA expression is observed (Szczylik et al,' Skorski et al," and our unpublished data). To determine whether p85a expression is essential for CML primary cell proliferation, as it is in cell lines dependent on BCWABL for proliferation, the growth of A-T-MNC and of CD34' CML primary cells exposed to p85a [SIODNs (80 + 40 + 40 pg/mL) was analyzed under optimal culture conditions with or without rIL-3 (Table I) . To compare the role of p85a in normal and malignant Ph'-dependent hematopoiesis, proliferation of normal marrow A-T-MNC and CD34' cells exposed to p85a [SIODNs was also determined under conditions allowing myeloid, erythroid, or megakaryocytic colony formation ( Table 2 ). Growth of CML cells treated with p85a sense [SIODNs was similar to that of control untreated cells. Instead, colony formation of CML-CP. CML-AP, and CML-BC (4, I , and 4 patients tested, respectively) in the presence or absence of IL-3 was significantly inhibited by treatment with p85a antisense [SIODNs in comparison with that of sense-treated groups (51 % to 92%. 54%, and 48% to 86% inhibition, respectively). Similarly, colony formation of A-T-or CD34"MNC was not affected by p85a sense [SIODNs treatment. In contrast, myelopoiesis and, even more so, erythropoiesis, but not megakaryopoiesis, were inhibited by p85a antisense [SIODNs treatment (32% to 62%, 66% to 90%. and 14% to 19%. respectively).
Effect of inhibition of PI-3 kinase activity by W o n proliferulion UJ BCWABL-ciependent leukemic and normal hematopoietic cells. To determine whether, as suggested by the above data, BCWABL-dependent growth of hematopoietic cells rests on expression of functional PI-3 kinase, proliferation assays were repeated on the BCWABL-dependent BV 173, Ba/F3B'WABL, DAGMRCWABL , and CML primary cells, on normal MNCs, and on the HL-60 and NB4 (BCW ABL-independent) cells cultured in the presence of the PI-3 kinase-specific inhibitor W P " added at 0.25 pmol/L (the lowest predetermined concentration for maximal inhibition of PI-3 kinase) every day during 4 consecutive days. At this concentration WT inhibited PI-3 kinase activity by about 95% in all cell lines and primary cells (not shown). The proliferation of BV173, Ba/F3RCWABL, and DAGMRCWARL cells, measured during 8-day culture, was significantly inhibited, whereas that of HL-60 and NB4 cells was unchanged compared with that of cells treated with diluent (DMSO) only (Fig 5) .
A-T-MNC and CD34' primary cells, obtained from the same patients or healthy donors used for the p85 studies, were cultured in the presence of 0.25 pmol/L WT (4 days) or diluent (DMSO) or were left untreated. Colony formation by CML-CP. CML-AP, and CML-BC cells in the presence of WT was inhibited by 48% to 74%. 75%, and 43% to 88% (in 3, I , and 4 patients), respectively, in comparison with control or diluent-treated cells (Table 3) . Lower concentrations of WT (0.0625 pmol/L) were still effective in inhibiting CML colony formation (data not shown). In only 1 patient (CML-CP 3) was the number of colonies not affected in these conditions. In contrast, myeloid, erythroid, and megakaryocytic colony formation by A-T-MNC and CD34' cells was not affected by the inhibitor (Table 4) under conditions in which PI-3 kinase activity was decreased by about 95% (not shown). Selective inhibitory effect of WT on leukemic cells. Primary cells from patient no. CML-BC 1 (cloning efficiency, -3%), in whom cytogenetic analysis indicated the presence of the Phl in 100% of the metaphases and molecular analysis showed expression of BCWABL transcripts containing the b2la2 breakpoint junction, were mixed with an equal number of A-T-MNC (cloning efficiency, -0.6%) and were incubated with 0.25 pmol/L of WT or diluent only, added every day for 5 days. Then, cells were washed and plated in HCC-4230 semisolid medium containing IL-3 for 12 days. BCW ABL transcripts were detectable in 7 of 10 individual colonies from the sample treated with DMSO only and in 1 of 10 colonies after WT treatment (Fig 6) . &Actin was detected in each of the colonies tested, excluding the possibility that BCWABL transcripts were undetectable because of loss of intact RNA during its preparation.
DISCUSSION
The pathway(s) by which the BCWABL proteins transduce signals to the nucleus to exert their transforming (leuke- mogenic) p~t e n t i a l~.~ has been intensively investigated. The identification of molecules that interact with BCWABL and of the mechanisms involved in their interactions may allow a better understanding of the leukemogenic process and identification of targets for antileukemia therapy. Among these molecules, PI-3 kinase has been shown to be directly associated (via its p85 subunit) with and activated by various normal and oncogenic tyrosine kinases, suggesting that it may regulate proliferation and/or other functions of normal and neoplastic ~e l l s .~' ,~~ To assess directly the role of BCWABL in the regulation of PI-3 kinase activity in Ph' cells, we investigated whether modulation of BCFUABL tyrosine kinase expression affects PI-3 kinase activity and, conversely, whether modulation of the expressiodfunction of this kinase affects proliferation of BCWABL-dependent cell lines and CML primary cells. The role of PI-3 kinase in colony fomation by normal hematopoietic cells was also evaluated.
To investigate the role of BCWABL in the regulation of PI-3 kinase activity, we used our previously described experimental models" in which inhibition of BCWABL expression is achieved in Ph' cells after treatment with bcrabl junction-specific antisense [SIODNs and transient expression of BCWABL is enforced by transfection of fi- broblasts. We show that BCWABL regulates PI-3 kinase enzymatic activity. To define the functional significance, if any, of this observation, we analyzed whether expression and/or function of PI-3 kinase are necessary for the BCW ABL-dependent proliferation of CML cells. The growth of normal erythropoietic and myelopoietic, but not megakaryopoietic, progenitors is also, at least in part, dependent on p85a expression. Inhibition of expression of the p85a subunit of PI-3 kinase resulted in inhibition of growth of BCW ABL-dependent cells but not of those that do not carry this translocation. This finding supports the specificity of the effects observed and indicates that PI-3 kinase is a downstream second messenger, the activity of which is necessary for BCWABL to transduce its mitogenic signal. Inhibition of expression of the p85 subunit of PI-3 kinase was achieved on treatment of the cells with antisense [SIODNs or transfection with plasmids expressing p85 antisense transcripts. Two p85 PI-3 kinase subunits (a and p with 62% homology) have been cloned from bovine tissue:3 and both can interact with the p1 l0 subunit." Each p85 subunit is independently regulated," suggesting that PI-3 kinase consisting of p85a-or p85P-pllO heterodimers may exert different roles in signal transduction. The human p85a-specific antisense [S]-ODNs used in these studies likely inhibited only expression of p85a-pl10 PI-3 kinase heterodimers, assuming that the human pS5p subunit (sequence not known) has the same degree of homology to p85a as that described for the a and p bovine subunits. Although we can not exclude that PI-3 kinase isoforms composed of different dimers are unable to transduce BCWABL-dependent signals resulting in proliferation, we consider this unlikely because (1) p85a represents more than 90% of the total cellular and (2) most PI-3 kinase activity in stimulated human lymphocytes is immunoprecipitated with ~8 5 a . 4~
Analogous to downregulated expression of p85cw, inhibition of PI-3 kinase activity by WT resulted in specific inhibition of BCWABL-dependent proliferation; however, colony formation from normal hematopoietic progenitors was not affected ( Table 4 and Fig 6) . W, at the concentrations used here, does not inhibit the activity of other enzymes (eg, cyclic nucleotide-dependent protein kinases, calmodulin-dependent protein kinase 11, mitogen-activated protein kinase, protein kinase C, PTK, and enzymes involved in cell respiratory activity),40,44,w8 indicating that the inhibitory effect of WT on BCWABL-dependent cell proliferation does not reflect toxicity. This observation, together with that of significant levels of PI-3 kinase activity in BCWABL-dependent cells and its induction in BCWABL-transformed cells, supports the conclusion that BCWABL induces PI-3 kinase activation, which is required for proliferation of CML cells. This is in agreement with the finding that PI-3 kinase is necessary for the stimulation of DNA synthesis after ligand activation of some (eg, platelet-derived growth factor receptor and epidermal growth factor but not all growth factor receptors. Because BCWABL not only induces proliferation, but also suppresses apoptosis:' it is possible that PI-3 kinase (p85 and/or p1 10 subunit) is involved in either one or both functions. Inhibition of normal myelopoiesis and erythropoiesis by p85a antisense fS]ODNs, bnt not by WT, raises the possibility that p85a serves as an independent signal transducer in normal hematopoiesis (such possibility has been already shown in the insulin receptor transduction pathway"), and that PI-3 kinase catalytic activity is not essential for proliferation of normal BM cells. The kinase is functionally activated by SCF, GM-CSF, M-CSF, and Epo and is physically associated with the ligand-activated thus, it may play a role in n o d hematopoiesis. However, it may not be required for stimulation of DNA synthesis, as already shown in M-CSF-stimulated cells." The finding that WT inhibits proliferation of BCWABL-dependent but not normal hematopoietic cells is apparently inconsistent with the data indicating that 0.25 pmoI/L WT inhibited PI-3 kinase by about 95% in both cell types, and that lack of effect of WT on proliferation of normal BM precursors also has to be reconciled with the observation that WT inhibits proliferation of growth factor-dependent cell lines at a concentration of 0.25 pmol/L (not shown). Perhaps, the presence of endogenously produced cytokine(s) and growth-promoting factors in n o d BM cultures can compensate for the inhibition of PI-3 kinase activity, whereas the requirement for one specific cytokine by growth factor-dependent cell lines is more sttingent. The differential sensitivity of CML and normal BM cells to WT could be exploited to purge leukemic cells from BM autografts, because we have shown that WT selectively inhibited CML, but not normal, hematopoietic colony formation from a mixture of normal and Ph' cells.
For personal use only. on July 28, 2017. by guest www.bloodjournal.org From For personal use only. on July 28, 2017. by guest www.bloodjournal.org From ported by the finding that PI-3 kinase activity coprecipitates with autophosphorylated, protein-activated tyrosine kinase variants of the ABL protein, including BCWABL.34 However, recent data5' also indicate that p21" can interact directly with the p110 subunit of PI-3 kinase in a guanosine tiphosphate-dependent manner through the ~2 1 "~ effector site and may regulate PI-3 kinase activity. Because p2lraS is regulated by BCWABL and, like PI-3 kinase, is required for the proliferation of Ph' cell^,"^'^ an alternative or additional possibility is that BCWABL stimulates the p110 subunit of PI-3 kinase via activation of ~2 1~' . These two mechanisms may cooperate. A third possibility worth considering is that stimulation of PI-3 kinase activity in CML cells is secondary to BCWABL-dependent stimulation of autocrine production of IL-3 and GM-CSF,53 especially because PI-3 kinase activity is inducible by GM-CSF. 54 The different effects of p85a antisense [SIODNs and WT on the growth of the CML-CP 3 cells (92.4% and 14% inhibition of colony formation, respectively) raise the possibility that p85 may interact not only with the p1 10 subunit of PI-3 kinase, but also with other molecule(s) involved in the BCWABL signal transduction pathway such as pl20GAP or p62. The recent report that p85 can associate with ~6 2 '~ and that the p62-pl20GAP complex may be linked to a p85 not associated with p1 10 supports this possibility. However, a specific function, if any, of the p85-p62-p120GAP complex has not been defined yet.
In summary, the data reported here provide the first direct evidence that PI-3 kinase (both p85 and p110 subunits) is involved in the proliferation of Ph' cells. Additional studies are necessary to dissect the molecular mechanisms regulating PI-3 kinase activity in BCWABL-dependent leukemic cells. Normal myelopoiesis and erythropoiesis, but not megakaryopoiesis, require expression of the p85a subunit, but the role of the p1 10 subunit needs to be investigated more carefully. The differential sensitivity to WT of normal and BCWABLdependent hematopoietic cells could be exploited for the selective elimination of CML cells (and, possibly, other tumor cells dependent on oncogenic tyrosine kinases) from BM autografts.
